Full Press Release Details
Supernus to Attend Guggenheim Securities
Boston Healthcare Conference
ROCKVILLE, Md., December 2, 2015 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company s management will be hosting investor meetings at the Guggenheim Securities 3rd Annual Boston Healthcare Conference 2015.
Date: Tuesday, December 15, 2015
Place: The Langham, Boston
Investors interested in arranging a meeting with the Company s management during this conference should contact the conference coordinator.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment and SPN-812 for ADHD.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.